For Healthcare Professionals Only.
Journal: American Journal of Clinical Dermatology ( ” Clinical Dermatology ” )
Validity Period (for CME): January 2026
(click to expand) Information for Doctor CME Category 3A (Self-study)
CME points will be awarded to doctors who submit claims for reading papers from Refereed Journals recommended by SMC or listed in PubMed. Papers must be published within the last 2 years. Claims from other publications, such as newsletters, magazines or non-refereed journals, will be rejected. This article serves as a concise overview of the key insights extracted from the original article. Hence, ensure to cite the actual research paper in your CME Cat. 3A claim. Link to the paper is provided in the footnotes. For more information, visit: [Criteria], [List]
(click to expand) Information for Pharmacist CPE Category 3A (Reading)
CPE points will be award to pharmacists who submit claims for reading papers from the list of journals recommended by the SPC if they wish to minimise the rejection of claims for reading non-recognised materials. This article serves as a concise overview of the key insights extracted from the original article. Hence, ensure to cite the actual research paper in your CPE Cat. 3A claim. Link to the paper is provided in the footnotes. For more information, visit: [Main], [Guide, Page 26], [List]
Introduction to Alopecia Areata (AA) and Current Treatment Landscape
- AA is an autoimmune disease characterized by nonscarring hair loss, ranging from small bald patches to complete loss of scalp, face, and/or body hair.
- It has an unpredictable course, potentially leading to chronic and extensive hair loss, including alopecia totalis or alopecia universalis.
- Prevalence is estimated at approximately 2%, and it significantly impacts patients’ quality of life, often leading to psychological and psychosocial symptoms.
Login to read more
